Following the MET mutant anti-cancer drug Tabrecta, which landed in Korea last year, Tepmetko is also undergoing a review.

MET mutations occur only in about 3-4% of non-small cell lung cancer patients, but the prognosis is poor, so there is a desperate need for treatments that are covered by benefits.

According to an industry on the 24th, the HIRA is considering establishing a new benefit standard for Tepmetko 225mg.

Tepmetko 225mg is an anticancer drug approved in Korea by Merck in November last year and is used to treat patients with local progressive or metastatic non-small cell lung cancer with MET Exxon 14 skipping confirmed. When MET Exxon 14 deficiency occurs, the ME